1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.

https://doi.org/10.3322/caac.21492

PMid:30207593 

2. Mohan SP, Bhaskaran MK, George AL, Thirutheri A, Somasundaran M, Pavithran A. Immunotherapy in Oral Cancer. J Pharm Bioallied Sci. 2019;11 Suppl 2:S107-11.

https://doi.org/10.4103/JPBS.JPBS_31_19

PMid:31198321 PMCid:PMC6555318

3. Calmeiro J, Carrascal MA, Tavares AR, Ferreira DA, Gomes C, Falcão A, et al. Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells. Pharmaceutics. 2020;15;12:158.

https://doi.org/10.3390/pharmaceutics12020158

PMid:32075343 PMCid:PMC7076373

4. Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, González-Moles MÁ, Kerr AR, et al. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 2020.

https://doi.org/10.1111/odi.13704

PMid:33128420 

5. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67:93-9.

https://doi.org/10.3322/caac.21388

PMid:28094848 

6. Padma R, Kalaivani A, Sundaresan S, Sathish P. The relationship between histological differentiation and disease recurrence of primary oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2017;21:461.

https://doi.org/10.4103/jomfp.JOMFP_241_16

PMid:29391735 PMCid:PMC5763883

7. Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:122-37.

https://doi.org/10.3322/caac.21389

PMid:28128848 

8. Lewis JS Jr, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med. 2018;142:559-97.

https://doi.org/10.5858/arpa.2017-0286-CP

PMid:29251996 

9. Picco G, Beatson R, Taylor-Papadimitriou J, Burchell JM. Targeting DNGR-1 (CLEC9A) with antibody/MUC1 peptide conjugates as a vaccine for carcinomas. Eur J Immunol. 2014;44:1947-55.

https://doi.org/10.1002/eji.201344076

PMid:24648154 PMCid:PMC4209794

10. Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. Cancer Cell. 2016;8;30:324-36.

https://doi.org/10.1016/j.ccell.2016.06.003

PMid:27424807 PMCid:PMC5374862

11. Yan Z, Wu Y, Du J, Li G, Wang S, Cao W, et al. A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy. Oncotarget. 2016;28;7:40437-50.

https://doi.org/10.18632/oncotarget.9624

PMid:27250027 PMCid:PMC5130018

12. Anne Gowda VM, Smitha T. The dendritic cell tool for oral cancer treatment. J Oral Maxillofac Pathol. 2019;23:326-9.

https://doi.org/10.4103/jomfp.JOMFP_325_19

PMid:31942108 PMCid:PMC6948037

13. Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J Immunother Cancer. 2019;18;7:109.

https://doi.org/10.1186/s40425-019-0580-6

PMid:30999964 PMCid:PMC6471787

14. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-15.

https://doi.org/10.1038/nm1100

PMid:15340416 PMCid:PMC1435696

15. Masterman KA, Haigh OL, Tullett KM, Leal-Rojas IM, Walpole C, Pearson FE, et al. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells. J Immunother Cancer. 2020;8:e000691.

https://doi.org/10.1136/jitc-2020-000691

PMid:32737142 PMCid:PMC7394304

16. Kim SJ, Kim G, Kim N, Chu H, Park BC, Yang JS, et al. Human CD141+ dendritic cells generated from adult peripheral blood monocytes. Cytotherapy. 2019;21:1049-63.

https://doi.org/10.1016/j.jcyt.2019.07.007

PMid:31447319 

17. Mastelic-Gavillet B, Sarivalasis A, Lozano LE, Wyss T, Inoges S, de Vries IJM, et al. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. Eur J Cancer. 2020;135:173-82.

https://doi.org/10.1016/j.ejca.2020.04.036

PMid:32590296 

18. Meyer MA, Baer JM, Knolhoff BL, Nywening TM, Panni RZ, Su X, et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat Commun. 2018;28;9:1250.

https://doi.org/10.1038/s41467-018-03600-6

PMid:29593283 PMCid:PMC5871846

19. Pearson FE, Tullett KM, Leal-Rojas IM, Haigh OL, Masterman KA, Walpole C, et al. Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141+ dendritic cells to activate naïve and memory WT1-specific CD8+ T cells. Clin Transl Immunology. 2020;12:9:e1141.

https://doi.org/10.1002/cti2.1141

PMid:32547743 PMCid:PMC7292901

20. Huang Z, Xie N, Liu H, Wan Y, Zhu Y, Zhang M, et al. The prognostic role of tumour-infiltrating lymphocytes in oral squamous cell carcinoma: A meta-analysis. J Oral Pathol Med. 2019;48:788-98.

https://doi.org/10.1111/jop.12927

PMid:31323145 

21. Li Y, Bai S, Carroll W, Dayan D, Dort JC, Heller K, et al. Validation of the risk model: high-risk classification and tumor pattern of invasion predict outcome for patients with low-stage oral cavity squamous cell carcinoma. Head Neck Pathol. 2013;7:211-23.

https://doi.org/10.1007/s12105-012-0412-1

PMid:23250819 PMCid:PMC3738758

22. Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, Hille JJ, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol. 2005;29:167-78.

https://doi.org/10.1097/01.pas.0000149687.90710.21

PMid:15644773 

23. de la Oliva J, Larque AB, Marti C, Bodalo-Torruella M, Nonell L, Nadal A, et al. Oral premalignant lesions of smokers and non-smokers show similar carcinogenic pathways and outcomes. A clinicopathological and molecular comparative analysis. J Oral Pathol Med. 2021;50:280-6.

https://doi.org/10.1111/jop.12864

PMid:31006144 

24. Conway DI, Purkayastha M, Chestnutt IG. The changing epidemiology of oral cancer: definitions, trends, and risk factors. Br Dent J. 2018;9;225:867-73.

https://doi.org/10.1038/sj.bdj.2018.922

PMid:30412558 

25. Dhanuthai K, Rojanawatsirivej S, Thosaporn W, Kintarak S, Subarnbhesaj A, Darling M, et al. Oral cancer: A multicenter study. Med Oral Patol Oral Cir Bucal. 2018;1;23:e23-e29.

PMID: 29274153